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Background. Human dendritic cell-specic intracellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN) is a 
mannose-binding lectin that initiates interaction between dendritic cells and resting T-lymphocytes. DC-SIGN is highly expressed 
in placental tissue on dendritic cells and Hoauer cells, and it is suggested that HIV may become adsorbed to DC-SIGN on 
Hoauer cells as part of the mechanism of mother-to-child HIV transmission. A possible mechanism of transfer of the virus from 
the Hoauer cells to the fetus is the subsequent adsorption to DC-SIGN-related molecules (DC-SIGNRs), present on immediately 
adjacent capillary vascular endothelium. However, data on DC-SIGN and DC-SIGNR expression in the placenta are few.
Methods. Forty term placentas from HIV-positive mothers and 21 term placentas from HIV-negative mothers underwent 
immunohistochemistry staining for DC-SIGN and DC-SIGNR expression. Five random sets of 10 villi were assessed, and the 
average number of positive cells were counted in each case. In addition, where possible, maternal and cord blood viral loads and 
maternal CD4+ counts were performed in the HIV-positive group only.
Results. e median maternal CD4+ count was 377 cells/µl and 27% of participants had undetectable viral loads; the median 
detectable viral load was 3.72 log. Most (97%) of the cord bloods tested in infants from HIV-positive mothers had lower than 
detectable viral loads. HIV-positive cases had signicantly greater expression of both DC-SIGNRs (median values in HIV-positive 
cases, 14.5 positive cells/10 villi (pc/10villi), compared with 11 pc/10villi in HIV-negative cases, p=0.020) and DC-SIGN (median 
value in HIV-positive cases, 26.5 pc/10villi, compared with 23 pc/10villi in HIV-negative cases, p=0.037). DC-SIGNR expression 
was also noted in Hoauer cells and decidual macrophages in addition to endothelium (reported currently). ere was no 
dierence in expression of DC-SIGN and DC-SIGNRs in patients with or without chorioamnionitis, but there was an inverse 
relationship between DC-SIGN and DC-SIGNR expression and maternal CD4+ counts in HIV-positive cases. 
Conclusion. Both DC-SIGN and DC-SIGNR expression were higher in placentas from HIV-positive mothers compared with 
HIV-negative cases. ese lectins may be potential new therapeutic targets for preventing vertical transmission of HIV. 
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e rate of vertical transmission of HIV is 
estimated at between 13% and 39% in non-
breastfeeding women.[1] Most of these cases 
occur during the intrapartum period during 
vaginal delivery. However, a small percentage 
results from HIV infection across the placenta (1 - 2%). A 
possible mechanism for late-gestation HIV transmission may be 
maternal-fetal transfusions during labour, which is signicantly 
lower in elective caesarean sections (CSs).[2]
Reverse transcriptase inhibitors (azidothymidine/zido-
vudine (AZT) and lamivudine) rapidly cross the placenta, 
and cord blood levels equal or exceed those in the maternal 
circulation at the time of delivery.[3] Even a single dose of 
nevirapine, when administered during labour and to an infant 
after birth, can reduce vertical transmission by 50% because 
it rapidly crosses the placenta.[3,4] The use of highly active 
antiretroviral therapy (HAART) throughout pregnancy and 
prophylactic CS have reduced the rate of vertical transmission 
in the US to <2%.[5] 
Infants with a positive HIV polymerase chain reaction (PCR) 
test within 48 hours of birth are considered to have been 
infected in utero. However, infants who tested HIV-negative at 
birth but tested positive at 6 weeks or 12 weeks postnatally with 
PCR testing are considered to have been infected intrapartum 
or immediately post partum.[6] In addition, HIV has been 
demonstrated in second-trimester fetuses and second-trimester 
cord bloods with associated placental HIV infection supporting 
in utero transmission.[7-9]
Factors that may increase the risk of mother-to-infant 
transmission include advanced HIV-related illness, low CD4+ 
counts, high HIV-1 viral loads (VLs), the presence of sexually 
transmitted diseases, viral phenotype, premature rupture 
of membranes, chorioamnionitis and absence of maternal 
autologous neutralising antibodies.[2] But even at the highest 
VLs, only about half of exposed infants become infected with 
HIV.[2,4]
It has been proposed that a breach in the trophoblast layer 
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(specialised fetal macrophages) with maternal 
blood and amniotic fluid. There may also 
be entry of HIV into the trophoblast layer 
with subsequent infection of the cell, or the 
virus could traverse the cells intact, following 
release at the basolateral surface and exposure 
to stromal cells. The two pathways are not 
mutually exclusive.[2] However, trophoblast 
cells are reported to be only ‘moderately 
susceptible’ to HIV infection in vitro.[10] It has 
been shown that tumour necrosis factor alpha 
(TNFα) significantly upregulated transcytosis 
of HIV-1 across the trophoblast layer 
whereas an anti-inflammatory drug (tenidap) 
significantly reduced transcytosis rates.[5]
Infection of trophoblast cells remains 
controversial.[11] C-C chemokine receptor 
type 5 (CCR5) and C-X-C chemokine receptor 
type 4 (CXCR4) were demonstrated on 
placental macrophages and lymphocytes, but 
not in trophoblast cells. 
Mattern et al.[12] demonstrated p24 antigen 
within scattered Hofbauer cells but not within 
trophoblast cells or vascular endothelium, in 
5/19 term placentas (26%) from HIV-positive 
women. There was no association between p24 
antigen detection and vertical transmission. [12] 
Another study showed positive Hofbauer 
cell staining for p24 in 4/9 (44%) placentas 
from HIV-positive mothers, but there was 
also decidual macrophage (n=1), intermediate 
trophoblast (n=1) and villous endothelium 
(n=1) positivity.[13]
Human dendritic cell-specific intracellular 
adhesion molecule-3 (ICAM3)-grabbing 
non-integrin (DC-SIGN) is a type II 
mannose-binding lectin that initiates 
interaction between dendritic cells and 
resting T-lymphocytes. It is highly expressed 
in dendritic cells on mucosal tissue and 
has also been found to be highly expressed 
in placental tissue on maternal decidual 
cells and fetal Hofbauer cells.[14] It has been 
proposed that HIV may become adsorbed 
to DC-SIGN on Hofbauer cells and/or infect 
Hofbauer cells. Various mechanisms have 
been proposed that may allow transfer of the 
virus from the Hofbauer cells to the fetus. 
One mechanism includes subsequent 
adsorp tion to DC-SIGN-related molecules 
(DC- SIGNRs) present on immediately 
adjacent capillary vascular endothelium. [14] 
A DC-SIGNR is a transmembrane lectin 
that binds mannose residues including the 
glycans of ICAM3 and HIV-1 and HIV-2. It 
is prominently expressed on endothelial cells 
derived from liver sinusoids, lymph node 
sinuses and placenta. [15] However, the possible 
role of DC-SIGN and DC-SIGNRs in vertical 
transmission of HIV is still poorly understood. 
The purpose of this study was to assess 
the expression of DC-SIGN and DC-SIGNRs 
in placentas of HIV-positive patients with 
the following objectives: to compare the 
expression of DC-SIGN and DC-SIGNRs in 
placentas of HIV-positive and HIV-negative 
patients; to correlate the expression of 
DC-SIGN and DC-SIGNRs with VLs, history 
of antiretroviral therapy and evidence of 
in-utero HIV transmission (if possible); and to 
assess the placentas from HIV-positive patients 
for pathology, including chorioamnionitis and 
the presence of specific infective agents.
Methods
Forty placentas from HIV-positive patients 
at term gestation were collected from the 
Department of Obstetrics and Gynaecology, 
Mowbray Maternity Hospital, Cape Town, 
South Africa. In addition, 21 placentas from 
HIV-negative patients were collected. Ethical 
approval for the study was granted by the 
Faculty of Health Sciences at the University of 
Cape Town and informed consent for research 
was obtained from the patients (REC REF 
290/2005).
The research included histology and 
immunohistochemistry of the placentas, 
performed in the Division of Anatomical 
Pathology, Groote Schuur Hospital, Cape 
Town. The placentas were fixed in 10% 
buffered formalin and analysed in the 
postmortem laboratory. The analysis included 
macroscopic description (with plate weight), 
serial sectioning and taking of three blocks, 
depending on the presence of macroscopic 
abnormality, which included umbilical 
cord, membranes, cord insertion site and a 
peripheral section of placenta. 
Haematoxylin and eosin stained sections 
were analysed by K Pillay and a placental 
histopathology report was issued. One suitable 
block was selected for immunohistochemistry. 
Two micrometre sections were cut onto 
poly-L-lysine coated slides and stained with 
DC-SIGN (purified mouse antihuman CD209 
antibody, dilution 1:40, BD Biosciences, 
US) and DC-SIGNRs (monoclonal 
antihuman CD209L antibody, dilution 1:40, 
R&D systems, US) using the Envision kit. 
Diaminobenzidine (brown) was used as 
chromogen. Positive and negative controls 
were run simultaneously.
Five random sets of 10 villi were assessed 
and an average number of positive cells were 
counted in each case. Maternal and fetal VLs, 
with blood taken at the time of delivery, 
were performed for the HIV-positive group 
in the Department of Virology, Groote Schuur 
Hospital, Cape Town.
Data were analysed using Stata Version 
10.0 (Stata Corporation, US). Median values 
of CD4+ cell count, HIV VL and DC-SIGNR 
expression were compared using the Wilcoxon 
rank-sum test; proportions were compared 
using Fisher’s exact test; and correlations were 
analysed using Spearman’s rho.
Results
Forty term placentas from HIV-positive 
mothers (mean age (range) 26 (14 - 38) years) 
and 21 term placentas from HIV-negative 
mothers (28 (16 - 40) years) were assessed.
All HIV-positive mothers received 
antiretrovirals for the prevention of mother-
to-child transmission (PMTCT). The majority 
started AZT monotherapy in the third 
trimester (85%, n=34), 2 were on AZT and 
nevirapine or lamivudine (5%) and 4 were 
on HAART before pregnancy (10%). Two of 
the 40 HIV-positive patients tested positive 
for syphilis (Venereal Disease Research 
Laboratory (VDRL)-positive) and received 
treatment for this, while none of the HIV-
negative mothers was VDRL-positive.
Most of the deliveries were by CS in both 
groups (Table 1). There were 2/38 (5%) 
small for gestational age (SGA) babies from 
HIV-positive mothers, one with a history 
of gestational proteinuric hypertension even 
though the placenta was histologically normal. 
There were 3/21 (14%) SGA babies from the 
HIV-negative cases, two of whom showed 
ischaemic changes histologically.
Table 1. Antenatal history and delivery
HIV status VDRL-positive Delivery SGA
HIV-positive (n=40) 2 10 NVD 2
30 CS
HIV-negative (n=21) 0 5 NVD 3
16 CS
VDRL = Venereal Disease Research Laboratory; NVD = normal vaginal delivery; CS = caesarean section;  
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In the HIV-positive group, the median 
maternal CD4+ count was 324.5 cells/µl 
(interquartile range 246 - 522) (n=38) and 27% 
of HIV-positive participants had undetectable 
VLs; the median detectable VL was 3.59 log 
(n=33).
In infants from HIV-positive mothers, 97% 
of the cord bloods tested had lower than 
detectable VLs (30/31). The mother of the 
infant with the positive cord blood (n=1) had 
higher than median VL, lower than median 
CD4+ count, received AZT, and the placenta 
showed chorioamnionitis with cord-vessel 
vasculitis and chronic deciduitis.
In the HIV-positive group, 15 placentas 
showed chorioamnionitis (grade 1 n=7, 
grade 2 n=6, grade 3 n=2; stage 1 n=3, stage 2 
n=9, stage 3 n=3). There was also plate-vessel 
vasculitis (n=9), cord-vessel vasculitis (n=7) 
and funisitis (n=2). In the HIV-negative group, 
there were three cases of chorioamnionitis 
(grade 2 n=2, grade 3 n=1; stage 1 n=1, 
stage 3 n=2) and two cases of mild cord-vessel 
vasculitis with no evidence of plate-vessel 
vasculitis or funisitis in this group.
There was no significant difference in 
the incidence of chorioamnionitis between 
placentas from HIV-positive and HIV-
negative mothers (p=0.084). There were 
9 cases of chronic deciduitis, 7 in HIV-
positive placentas and 2 in HIV-negative 
patients (p=0.704). There was no evidence of 
villitis or intervillositis, and no opportunistic 
infections (e.g. cytomegalovirus inclusions, 
toxoplasmosis or cryptococcosis) were noted 
on morphology.
Additional features that were noted on 
histology in the HIV-positive group included 
evidence of meconium exposure (n=10), focal 
infarct (n=1), focal decidual vasculopathy 
(n=1), dysmaturity (n=3), fetal thrombotic 
vasculopathy (n=1), chorangiosis (n=1), 
intervillous thrombus (n=2) and intervillous 
haemorrhage (n=3); and in the HIV-negative 
group, infarcts (n=2), decidual vasculopathy 
(n=1) and dysmaturity (n=2).
DC-SIGN expression was noted in Hofbauer 
cells (Fig. 1) and decidual macrophages (Fig. 2) 
while DC-SIGNR expression was seen in 
endothelial cells (Fig. 3), some Hofbauer cells 
and decidual macrophages (Fig. 4). Decidual 
macrophage staining for DC-SIGNRs has not 
been described previously in the literature. 
HIV-positive cases had significantly greater 
expression of both DC-SIGNRs (median 
values in HIV-positive cases, 14.5 positive 
cells/10 villi (pc/10villi), compared with 
11 pc/10villi in HIV-negative cases, p=0.020) 
and DC-SIGN (median values in HIV-
positive cases, 26.5 pc/10villi, compared with 
23 pc/10villi in HIV-negative cases, p=0.037). 
In addition, the expression of DC-SIGN 
and DC-SIGNRs was inversely associated with 
CD4+ count in HIV-positive cases (p<0.05 
for both, Fig. 5) but the relationship with 
maternal VL was not statistically significant. 
There was no significant difference in the 
expression of DC-SIGN (p=0.833) and 
DC-SIGNRs (p=0.557) in placentas with or 
without placental membrane inflammation. 
There was also no association with mode of 
delivery (normal vaginal delivery v. CS).
Discussion
In the placenta, no co-expression of DC-SIGN 
and DC-SIGNRs was detected previously. [15] 
DC-SIGNR expression was detected only 
on capillary endothelial cells, whereas DC-
SIGN was expressed only by Ho auer cells. [15] 
However, Mummidi et al.[16] demonstrated 
expression of DC-SIGN on placental capillary 
endothelium as well. DC-SIGNRs showed a 
low level of expression in the endometrium. [17] 
In this study, we demonstrated DC-SIGNR 
expression on Ho auer cells and decidual 
cells as well. 
DC-SIGN and DC-SIGNR lectins have been 
shown to mediate infection in cis (cells with 
DC-SIGN receptors e.g. dendritic cells) and 
trans (e.g. T-lymphocytes) cells.[18] Currently, 
it is felt that DC-SIGN and DC-SIGNRs 
represent the best candidate molecules for 
mediating intrauterine transmission.[10] 
DC-SIGN and DC-SIGNRs appear to function 
Fig. 1. A. DC-SIGN expression in Hofbauer cells in 
an HIV-positive case with chorioamnionitis and a 
CD4+ count of 118 cells/µl; B. DC-SIGN expression 
in Hofbauer cells in an HIV-negative case. (DC-
SIGN = human dendritic cell-speci c intracellular 




Fig. 2. DC-SIGN expression in decidual 
macrophages in an HIV-positive case with the 
only detectable viral load in the cord blood. (DC-
SIGN = human dendritic cell-speci c intracellular 
adhesion molecule-3 (ICAM3)-grabbing non-
integrin.)
Fig. 3. DC-SIGNR expression in endothelial cells 
and Hofbauer cells in an HIV-positive case with 
maternal CD4+ count of 365 cells/µl and a viral 
load of 3.84 log. (DC-SIGNR = human dendritic cell-
speci c intracellular adhesion molecule-3 (ICAM3)-
grabbing non-integrin-related molecule.)
Fig. 4. DC-SIGNR expression in decidual macro-
phages in an HIV-positive case with  maternal 
CD4+ count of 45 cells/µl. (DC-SIGNR = human 
dendritic cell-speci c intracellular adhesion 
molecule-3 (ICAM3)-grabbing non-integrin-
related molecule.)












as universal attachment factors for primate 
lentiviruses, namely HIV-1, HIV-2 and simian 
immunodeficiency viruses. [19] However, 
research in this field is still in progress and 
many studies are in vitro in nature. One such 
study has shown a decrease in DC-SIGN 
expression following infection with HHV- 6. [20,21] 
According to these papers, this may apply to the 
infection of HIV-1, or DC-SIGN expression 
may be up-regulated in the setting of HIV-1. 
Another in-vitro study has shown that while 
DC-SIGN is up-regulated by type 1 and type 2 
cytokines, there is no association between 
DC-SIGN expression and the degree of HIV-1 
transmission from macrophages to CD4+ 
T-cells.[21] The situation in vivo may be different.
A few studies have shown that anti-
DC-SIGN reactive antibodies block 
HIV transmission to cells mediated by 
DC-SIGN. [22] If studies find a significant 
association between DC-SIGN expression and 
intrauterine transmission, then transplacental 
transmission of HIV may be retarded by the 
administration of DC-SIGN- and DC-SIGNR-
blocking molecules. Other lectin receptors 
include mannose receptor and langerin 
expressed on intradermal dendritic cells 
and Langerhans cells (DC-SIGN negative), 
respectively, which may have HIV-binding 
affinity.[23] DC-SIGN on dendritic cells has 
been shown to bind and transfer HIV through 
its interaction with HIV gp120. Disruption 
of this interaction represents a potential new 
therapeutic approach for preventing HIV 
transmission.[24] 
Gurney et al.[24] found that DC-SIGN-
positive dendritic cells in the submucosa may 
be responsible for the transfer of HIV-1 from 
the periphery to the draining lymph nodes 
during primary sexual mucosal transmission 
of HIV-1. DC-SIGN-positive cells appear to be 
immature dendritic cells in that they did not 
express the dendritic cell maturation molecule 
CD83. The Hofbauer cells have also been 
shown to be human leukocyte antigen (HLA) 
II+ , CD68+, CD14 low+, CD4+, and S100±, 
CD86– and CMRF-44–. [23,25]
DC-SIGN is also expressed by some decidual 
cells with CD14high+ and S100-negative 
phenotype compared with the Hofbauer cells. 
DC-SIGN-positive Hofbauer cells co-express 
CD4+ and chemokine receptors CCR-5 and 
CXCR4.[23] Gurney et al.[24] have demonstrated 
an increase in DC-SIGN-positive cells in the gut 
mucosa of HIV-positive patients (two - four-
fold greater). Increased DC-SIGN expression 
in the gut mucosa correlated with a type 2 
environment (increased interleukin (IL)-10/
IL-12 ratio) and a decrease in the levels of the 
costimulatory molecules CD86 and CD80.
Micro-array analysis experiments have 
shown that IL-10-induced dendritic cells 
result in a DC-SIGN high-expressing subset. 
There is a shift in pregnancy towards the 
production of T-helper 2 (Th2) cytokines, 
including IL-4 and IL-10, promoted by 
progesterone.[4] The Th2 cytokines IL-4 and 
IL-13 play an important role in inducing 
DC-SIGN expression under specific 
conditions.[23] However, it has been shown 
that placentas from non-transmitting women 
maintain normal type 2 placental cytokines 
(IL-4, IL-10) whereas transmitting women 
have placentas that express type 1 cytokines 
(interferon-gamma, tumour necrosis factor 
beta).[11] Other cytokines (TNFα, IL-6, etc.) 
stimulate the HIV infection and facilitate 
transmission during pregnancy.[2] 
In this study, we found an increase in 
DC-SIGN expression in placentas from HIV-
positive patients, which may be due to the 
increased cytokine milieu. 
Fig. 5. A. CD4+ v. DC-SIGNRs (CD299) showing a statistically signicant inverse correlation, the higher 
the expression, the lower the CD4+ count; B. CD4+ v. DC-SIGN (CD209) showing a statistically signicant 
inverse correlation, the higher the expression, the lower the CD4+ count. (DC-SIGNR = human dendritic 
cell-specic intracellular adhesion molecule-3 (ICAM3)-grabbing non-integrin-related molecules.)
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It has been shown that an anti-DC-SIGN antibody blocked virus 
binding to dendritic cells by almost 90%, with low viral inocula close to 
those found in seminal uid from untreated HIV-positive patients.[24] In 
addition, when the HIV was exposed to the total mucosal mononuclear 
cells, about 40-fold more viruses were bound to the DC-SIGN-positive 
population compared with the total gut mononuclear cell population. 
erefore, more than 90% of the bound virus was associated with the 
DC-SIGN-positive cells, which only constitute about 1 - 5% of the total 
mucosal mononuclear cell population. DC-SIGN is therefore a potential 
target for therapeutic intervention to reduce viral transmission (aer 
sexual transmission and during vertical transmission).[14,24] e ability 
of DC-SIGN to enhance infection markedly when virus levels are low 
may be of particular importance in the setting of prophylaxis against 
mother-to-child transmission and HAART.[26]
Placental membrane inflammation comprises histological evidence of 
chorioamnionitis and/or funisitis with or without associated vasculitis. 
Plasma cell (chronic) deciduitis is demonstrated by the presence of 
plasma cells in the maternal decidua.[27]
Jauniaux et al.[28] demonstrated a high incidence of chorioamnionitis 
(43%) in placentas from HIV-positive women, but villitis was absent. 
According to the study by Schwartz et al.,[29] no histopathological 
finding occurred with increased frequency in placentas of transmitting 
women even though there was a trend towards increased frequency of 
plasma cell deciduitis. Only 1/17 transmitting women had a placenta 
with low-grade neutrophilic inflammation. More uninfected women 
had villitis.[29] Chandwani et al.[30] demonstrated no cases of villitis and a 
higher incidence of chorionitis in placentas from HIV-positive women 
and p24 antigen within trophoblastic cells, contrary to other studies.[30]
In our study, we demonstrated no significant difference in placental 
membrane inflammation or chronic deciduitis between HIV-positive 
and HIV-negative women. There were no cases of villitis or intervillositis 
in any of the cases. In addition, there was no association of DC-SIGN or 
DC-SIGNR expression with placental membrane inflammation.
Conclusion
Both DC-SIGN and DC-SIGNR expression were higher in placentas 
from HIV-positive mothers compared with HIV-negative cases, and 
this was statistically signicant. DC-SIGNR expression was also noted 
in Hoauer cells and decidual macrophages in addition to endothelium 
(reported currently). ere was no association of DC-SIGN or 
DC-SIGNR expression with the presence of placental membrane 
inammation, but there was a statistically signicant inverse relationship 
between DC-SIGN and DC-SIGNR expression and maternal CD4+ 
counts in HIV-positive cases. ere was possible in utero transmission 
of HIV in one of the 40 HIV-positive cases (3%).
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